Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

NCT00004645 is registered in ClinicalTrials.gov with National Institute of Neurological Disorders and Stroke (NINDS) as lead sponsor.

NCT NCT00004645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 1995
Completion date
Not reported
Enrollment
22
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute disseminated encephalomyelitis, acute transverse myelitis, balo's concentric sclerosis, devic's syndrome, marburg's variant of multiple sclerosis